Kerkhofs TM, Verhoeven RH, Van der Zwan JM, Dieleman J, Kerstens MN, Links TP, Van de Poll-Franse LV, Haak HR. Adrenocortical carcinoma: a population-based study on incidence and survival in the Netherlands since 1993. Eur J Cancer. 2013;49:2579–86.

Article  PubMed  Google Scholar 

Vanbrabant T, Fassnacht M, Assie G, Dekkers O. Influence of hormonal functional status on survival in adrenocortical carcinoma: systematic review and meta-analysis. Eur J Endocrinol. 2018;179:429–36.

Article  CAS  PubMed  Google Scholar 

Fassnacht M, Johanssen S, Quinkler M, Bucsky P, Willenberg HS, Beuschlein F, Terzolo M, Mueller HH, Hahner S, Allolio B. Limited prognostic value of the 2004 International Union Against Cancer staging classification for adrenocortical carcinoma: proposal for a Revised TNM Classification. Cancer. 2009;115:243–50.

Article  PubMed  Google Scholar 

Glenn JA, Else T, Hughes DT, Cohen MS, Jolly S, Giordano TJ, Worden FP, Gauger PG, Hammer GD, Miller BS. Longitudinal patterns of recurrence in patients with adrenocortical carcinoma. Surgery. 2019;165:186–95.

Article  PubMed  Google Scholar 

•• Fassnacht M, Assie G, Baudin E, Eisenhofer G, De La Fouchardiere C, Haak H, De Krijger R, Porpiglia F, Terzolo M, Berruti A. Adrenocortical carcinomas and malignant phaeochromocytomas: ESMO–EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2020;31:1476–90.This is a latest clinical practice guidelines for diagnosis and treatment of ACC.

Article  CAS  PubMed  Google Scholar 

Lughezzani G, Sun M, Perrotte P, Jeldres C, Alasker A, Isbarn H, Budäus L, Shariat SF, Guazzoni G, Montorsi F. The European Network for the Study of Adrenal Tumors staging system is prognostically superior to the international union against cancer-staging system: a North American validation. Eur J Cancer. 2010;46:713–9.

Article  PubMed  Google Scholar 

Elhassan YS, Altieri B, Berhane S, Cosentini D, Calabrese A, Haissaguerre M, Kastelan D, Fragoso M, Bertherat J, Al Ghuzlan A, Haak H, Boudina M, Canu L, Loli P, Sherlock M, Kimpel O, Lagana M, Sitch AJ, Kroiss M, Arlt W, Terzolo M, Berruti A, Deeks JJ, Libe R, Fassnacht M, Ronchi CL. S-GRAS score for prognostic classification of adrenocortical carcinoma: an international, multicenter ENSAT study. Eur J Endocrinol. 2021;186:25–36. https://doi.org/10.1530/EJE-21-0510.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Libe R, Borget I, Ronchi CL, Zaggia B, Kroiss M, Kerkhofs T, Bertherat J, Volante M, Quinkler M, Chabre O, Bala M, Tabarin A, Beuschlein F, Vezzosi D, Deutschbein T, Borson-Chazot F, Hermsen I, Stell A, Fottner C, Leboulleux S, Hahner S, Mannelli M, Berruti A, Haak H, Terzolo M, Fassnacht M, Baudin E, network E. Prognostic factors in stage III-IV adrenocortical carcinomas (ACC): an European Network for the Study of Adrenal Tumor (ENSAT) study. Ann Oncol. 2015;26:2119–25. https://doi.org/10.1093/annonc/mdv329.

Article  CAS  PubMed  Google Scholar 

Beuschlein F, Weigel J, Saeger W, Kroiss M, Wild V, Daffara F, Libé R, Ardito A, Al Ghuzlan A, Quinkler M. Major prognostic role of Ki67 in localized adrenocortical carcinoma after complete resection. J Clin Endocrinol Metab. 2015;100:841–9.

Article  CAS  PubMed  Google Scholar 

Giordano TJ, Thomas DG, Kuick R, Lizyness M, Misek DE, Smith AL, Sanders D, Aljundi RT, Gauger PG, Thompson NW. Distinct transcriptional profiles of adrenocortical tumors uncovered by DNA microarray analysis. Am J Pathol. 2003;162:521–31.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Tissier F, Cavard C, Groussin L, Perlemoine K, Fumey G, Hagneré A-M, René-Corail F, Jullian E, Gicquel C, Bertagna X. Mutations of β-catenin in adrenocortical tumors: activation of the Wnt signaling pathway is a frequent event in both benign and malignant adrenocortical tumors. Can Res. 2005;65:7622–7.

Article  CAS  Google Scholar 

Zheng S, Cherniack AD, Dewal N, Moffitt RA, Danilova L, Murray BA, Lerario AM, Else T, Knijnenburg TA, Ciriello G. Comprehensive pan-genomic characterization of adrenocortical carcinoma. Cancer Cell. 2016;29:723–36.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Assie G, Letouze E, Fassnacht M, Jouinot A, Luscap W, Barreau O, Omeiri H, Rodriguez S, Perlemoine K, Rene-Corail F, Elarouci N, Sbiera S, Kroiss M, Allolio B, Waldmann J, Quinkler M, Mannelli M, Mantero F, Papathomas T, De Krijger R, Tabarin A, Kerlan V, Baudin E, Tissier F, Dousset B, Groussin L, Amar L, Clauser E, Bertagna X, Ragazzon B, Beuschlein F, Libe R, de Reynies A, Bertherat J. Integrated genomic characterization of adrenocortical carcinoma. Nat Genet. 2014;46:607–12. https://doi.org/10.1038/ng.2953.

Article  CAS  PubMed  Google Scholar 

Gara SK, Lack J, Zhang L, Harris E, Cam M, Kebebew E. Metastatic adrenocortical carcinoma displays higher mutation rate and tumor heterogeneity than primary tumors. Nat Commun. 2018;9:4172. https://doi.org/10.1038/s41467-018-06366-z.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Corso CR, Acco A, Bach C, Bonatto SJR, de Figueiredo BC, de Souza LM. Pharmacological profile and effects of mitotane in adrenocortical carcinoma. Br J Clin Pharmacol. 2021;87:2698–710. https://doi.org/10.1111/bcp.14721.

Article  PubMed  Google Scholar 

Sbiera S, Leich E, Liebisch G, Sbiera I, Schirbel A, Wiemer L, Matysik S, Eckhardt C, Gardill F, Gehl A, Kendl S, Weigand I, Bala M, Ronchi CL, Deutschbein T, Schmitz G, Rosenwald A, Allolio B, Fassnacht M, Kroiss M. Mitotane inhibits Sterol-O-Acyl Transferase 1 triggering lipid-mediated endoplasmic reticulum stress and apoptosis in adrenocortical carcinoma cells. Endocrinology. 2015;156:3895–908. https://doi.org/10.1210/en.2015-1367.

Article  CAS  PubMed  Google Scholar 

Terzolo M, Angeli A, Fassnacht M, Daffara F, Tauchmanova L, Conton PA, Rossetto R, Buci L, Sperone P, Grossrubatscher E. Adjuvant mitotane treatment for adrenocortical carcinoma. N Engl J Med. 2007;356:2372–80.

Article  CAS  PubMed  Google Scholar 

Terzolo M, Fassnacht M, Perotti P, Libé R, Kastelan D, Lacroix A, Arlt W, Haak HR, Loli P, Decoudier B. Adjuvant mitotane versus surveillance in low-grade, localised adrenocortical carcinoma (ADIUVO): an international, multicentre, open-label, randomised, phase 3 trial and observational study. Lancet Diabetes Endocrinol. 2023;11:720–30.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Fassnacht M, Dekkers OM, Else T, Baudin E, Berruti A, De Krijger RR, Haak HR, Mihai R, Assie G, Terzolo M. European Society of Endocrinology Clinical Practice Guidelines on the management of adrenocortical carcinoma in adults, in collaboration with the European Network for the Study of Adrenal Tumors. Eur J Endocrinol. 2018;179:G1–46.

Article  CAS  PubMed  Google Scholar 

Reidy-Lagunes DL, Lung B, Untch BR, Raj N, Hrabovsky A, Kelly C, Gerst S, Katz S, Kampel L, Chou J. Complete responses to mitotane in metastatic adrenocortical carcinoma—a new look at an old drug. Oncologist. 2017;22:1102–6.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Megerle F, Herrmann W, Schloetelburg W, Ronchi CL, Pulzer A, Quinkler M, Beuschlein F, Hahner S, Kroiss M, Fassnacht M, Group GAS. Mitotane monotherapy in patients with advanced adrenocortical carcinoma. J Clin Endocrinol Metab. 2018;103:1686–95. https://doi.org/10.1210/jc.2017-02591.

Article  Google Scholar 

Kerkhofs T, Baudin E, Terzolo M, Allolio B, Chadarevian R, Mueller H, Skogseid B, Leboulleux S, Mantero F, Haak H. Comparison of two mitotane starting dose regimens in patients with advanced adrenocortical carcinoma. J Clin Endocrinol Metab. 2013;98:4759–67.

Article  CAS  PubMed  Google Scholar 

Hermsen IG, Fassnacht M, Terzolo M, Houterman S, den Hartigh J, Leboulleux S, Daffara F, Berruti A, Chadarevian R, Schlumberger M. Plasma concentrations of o, p′ DDD, o, p′ DDA, and o, p′ DDE as predictors of tumor response to mitotane in adrenocortical carcinoma: results of a retrospective ENS@ T multicenter study. J Clin Endocrinol Metab. 2011;96:1844–51.

Article  CAS  PubMed  Google Scholar 

Puglisi S, Calabrese A, Basile V, Ceccato F, Scaroni C, Altieri B, Della Casa S, Loli P, Pivonello R, De Martino MC, Canu L, Russo M, Badalamenti G, Torlontano M, Stigliano A, Ferraù F, Arnaldi G, Saba L, Quirino A, Perotti P, Berchialla P, Terzolo M. Mitotane concentrations influence outcome in patients with advanced adrenocortical carcinoma. Cancers. 2020;12:740.

Article  PubMed  PubMed Central  Google Scholar 

Baudin E, Pellegriti G, Bonnay M, Penfornis A, Laplanche A, Vassal G, Schlumberger M. Impact of monitoring plasma 1, 1-dichlorodiphenildichloroethane (o, p′ DDD) levels on the treatment of patients with adrenocortical carcinoma. Cancer. 2001;92:1385–92.

Article  CAS  PubMed  Google Scholar 

Fassnacht M, Terzolo M, Allolio B, Baudin E, Haak H, Berruti A, Welin S, Schade-Brittinger C, Lacroix A, Jarzab B. Combination chemotherapy in advanced adrenocortical carcinoma. N Engl J Med. 2012;366:2189–97.

Article  CAS  PubMed  Google Scholar 

Sperone P, Ferrero A, Daffara F, Priola A, Zaggia B, Volante M, Santini D, Vincenzi B, Badalamenti G, Intrivici C, Del Buono S, De Francia S, Kalomirakis E, Ratti R, Angeli A, Dogliotti L, Papotti M, Terzolo M, Berruti A. Gemcitabine plus metronomic 5-fluorouracil or capecitabine as a second-/third-line chemotherapy in advanced adrenocortical carcinoma: a multicenter phase II study. Endocr Relat Cancer. 2010;17:445–53. https://doi.org/10.1677/erc-09-0281.

Article  CAS  PubMed  Google Scholar 

Creemers S, Van Koetsveld P, Van Den Dungen E, Korpershoek E, van Kemenade F, Franssen G, de Herder W, Feelders R, Hofland L. Inhibition of human adrenocortical cancer cell growth by temozolomide in vitro and the role of the MGMT gene. J Clin Endocrinol Metab. 2016;101:4574–84.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Cosentini D, Badalamenti G, Grisanti S, Basile V, Rapa I, Cerri S, Spallanzani A, Perotti P, Musso E, Laganà M. Activity and safety of temozolomide in advanced adrenocortical carcinoma patients. Eur J Endocrinol. 2019;181:681–9.

Article  CAS  PubMed  Google Scholar 

De Fraipont F, El Atifi M, Cherradi N, Le Moigne G, Defaye G, Houlgatte R, Bertherat J, Bertagna X, Plouin P-F, Baudin E. Gene expression profiling of human adrenocortical tumors using complementary deoxyribonucleic acid microarrays identifies several candidate genes as markers of malignancy. J Clin Endocrinol Metab. 2005;90:1819–29.

Article  PubMed  Google Scholar